Background Novel oral anticoagulants and warfarin are widely used for stroke prevention in
patients with atrial fibrillation. The anticoagulation status of patients receiving warfarin or …

Patients with atrial fibrillation are at an increased risk for stroke. Anticoagulation therapy has
been shown to significantly reduce the risk for stroke in these patients. Warfarin therapy is …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved
for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has …

Background Warfarin is commonly used as a secondary prevention of stroke in patients with
atrial fibrillation (AF). However, limitations have been observed even with the use of this …

For patients with atrial fibrillation, anticoagulant therapy is essential to reduce the risk of
ischemic stroke that is associated with this arrhythmia. Historically, warfarin has been the …

Stroke is a major health problem worldwide, and is often fatal or associated with poor long-
term outcomes. Atrial fibrillation (AF) is responsible for up to 20% of all strokes; and the risk …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background—Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral
factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in …

Background—Renal impairment increases the risk of stroke and bleeding in patients with
atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) …

Atrial fibrillation (AF) is an important risk factor for cardioembolic stroke. Warfarin is an
effective treatment in reducing the risk of cardioembolic stroke in patients with AF. New …